Inaugural Lecture of Prof. Szente at the Hungarian Academy of Sciences
Lajos Szente, Ph.D., D.Sc., one of the founders and former CEO (now Scientific Advisor) of CycloLab at the company and
Tag: SBECD
Cyclodextrin-based delivery systems in parenteral formulations: A critical update review
Amongst all the strategies that can be useful in the development of parenteral formulations, the formation of water-soluble host-guest inclusion
Nano-formulations containing SBECD
Various nano-formulations containing SBECD have been studied in order to utilize the inclusion complex forming (solubilizing, stabilizing) ability of this
Clinical trial: Allopregnalonone/Dexolve for Post Traumatic Stress Disorder
About 6.4% of the U.S. population suffers from posttraumatic stress disorder (PTSD). Trauma-focused psychotherapies are generally effective in PTSD, but
SBEβCD-based nanodelivery system targeting the brain
Neuroinflammation occurs early in Alzheimer’s disease (AD). The initial stage of AD is related to glial dysfunction, which contributes to
Antidote-like Effect of Cyclodextrins on Plant Neurotoxin Veratridine
Veratridine (VTD) is a plant neurotoxin that acts by blocking the voltage-gated sodium channels (VGSC) of cell membranes. Symptoms of
Insulin Complexation with Cyclodextrins—A Molecular Modeling Approach
Around 5% of the population of the world is affected with the disease called diabetes mellitus. The main medication of
Molecular docking assisted exploration on solubilization of poorly soluble drug remdesivir in sulfobutyl ether-beta-cyclodextrin
In terms of solubilization effect, it was found that phase solubility of RDV increased significantly from intrinsic 1.7 mmol/L at
Buccal administration of remdesivir – still far from reality
As remdesivir, the first FDA-approved drug for SARS-CoV-2 infection, can be used only for hospitalized patients due to intravenous administration,
Remdesivir administration for Japanese COVID-19 patients undergoing maintenance hemodialysis: a retrospective observation with six case reports
The mortality rate of novel coronaviral disease (COVID-19) patients undergoing dialysis is considerably higher than that of patients with normal